USPTO Examiner BEGEMAN ANDREW W - Art Unit 3798

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18741279ULTRASONIC DEVICE FOR COUPLING AN ULTRASONIC COUPLING GEL AND ULTRASONIC HEADJune 2024June 2025Allow1230YesNo
18526848DETECTING FLUID FLOWS USING ULTRASOUND IMAGING SYSTEMSDecember 2023August 2024Allow800YesNo
18307094MAGNETOCARDIOGRAPHY MEASURING APPARATUSApril 2023May 2025Allow2510NoNo
18300292ULTRASONIC DEVICE FOR COUPLING AN ULTRASONIC COUPLING GEL AND ULTRASONIC HEADApril 2023March 2024Allow1130YesNo
18105207Intraoperative Ultrasound Probe System and Related MethodsFebruary 2023March 2025Abandon2510NoNo
17872717Large Vessel Occlusion Alert from Optical MeasurementsJuly 2022May 2025Abandon3310NoNo
17788416DEVICE FOR MONITORING HIFU TREATMENTSJune 2022February 2025Abandon3210NoNo
17841489Wearable Imaging System for Measuring Bone DisplacementJune 2022February 2025Allow3210YesNo
17831611ULTRASOUND IMAGING APPARATUS, ULTRASOUND IMAGING SYSTEM, METHOD OF OPERATING ULTRASOUND IMAGING APPARATUS, COMPUTER-READABLE RECORDING MEDIUM, AND ULTRASOUND ENDOSCOPE SYSTEMJune 2022December 2024Abandon3110YesNo
17764029RECORDING ULTRASOUND IMAGESMarch 2022February 2025Abandon3420NoNo
17652591ULTRASONIC DIAGNOSTIC APPARATUS, DETERMINATION METHOD, AND DETERMINATION PROGRAMFebruary 2022March 2025Abandon3740YesNo
17581439Actively Cooled Ultrasound Probe with Additively Manufactured Heat ExchangerJanuary 2022June 2025Abandon4160YesNo
17551785METHOD AND SYSTEM FOR CAPTURING AND SUMMARIZING CHANGES IN ULTRASOUND SCANNING SETTINGSDecember 2021April 2024Abandon2820NoNo
17455208ULTRASOUND POSITIONING DEVICE, SYSTEM, AND METHODNovember 2021November 2024Abandon3610NoNo
17506180METHOD AND SYSTEM FOR CHARACTERIZING VALVULAR REGURGITATION/INSUFFICIENCY FROM SEQUENCES OF IMAGESOctober 2021December 2024Allow3730YesNo
17604941ANATOMICAL STRUCTURE IDENTIFICATION APPARATUS AND DISPLAY METHOD THEREOFOctober 2021October 2024Allow3640NoNo
17412696ACTIVELY DAMPED ULTRASONIC TRANSDUCERAugust 2021January 2025Abandon4040YesNo
17444336METHODS, SYSTEMS, AND DEVICES FOR ANALYZING LUNG IMAGING DATA TO DETERMINE COLLATERAL VENTILATIONAugust 2021March 2024Allow3111YesNo
17305603ULTRASONIC DIAGNOSTIC APPARATUS AND STORAGE MEDIUMJuly 2021October 2024Abandon3940YesNo
17373015APPARATUS AND METHOD FOR ESTIMATING BLOOD PRESSUREJuly 2021November 2024Allow4020NoNo
17315096Automated Three and Four-Dimensional Ultrasound Quantification and Surveillance of Free Fluid in Body Cavities and Intravascular VolumeMay 2021January 2024Abandon3220NoNo
17239335DISPLAYING BLOOD VESSELS IN ULTRASOUND IMAGESApril 2021March 2025Allow4741YesNo
17202508ELECTRONIC DEVICE, CONTROL METHOD FOR THE ELECTRONIC DEVICE, AND STORAGE MEDIUMMarch 2021December 2024Allow4540YesNo
17195405METHOD FOR PROVIDING FRACTURE-DETECTION TOOLMarch 2021November 2023Allow3210NoNo
17115966METHOD AND APPARATUS FOR QUANTITATIVE IMAGING USING ULTRASOUND DATADecember 2020March 2025Allow5141NoNo
16950046JOINT ASSESSMENT OF MYOCARDIAL STRAIN AND INTRACARDIAC BLOOD FLOWNovember 2020October 2024Abandon4740NoNo
17062917METHOD FOR MAINTAINING LOCALIZATION OF DISTAL CATHETER TIP TO TARGET DURING VENTILATION AND/OR CARDIAC CYCLESOctober 2020December 2024Abandon5020YesNo
17003247METHOD AND SYSTEM FOR PROVIDING AN ANATOMIC ORIENTATION INDICATOR WITH A PATIENT-SPECIFIC MODEL OF AN ANATOMICAL STRUCTURE OF INTEREST EXTRACTED FROM A THREE-DIMENSIONAL ULTRASOUND VOLUMEAugust 2020January 2024Allow4040YesYes
16765327METHOD AND APPARATUS FOR GUIDING AN ULTRASOUND PROBEMay 2020July 2024Abandon4940YesNo
16876185MATERIAL DECOMPOSITION APPARATUS, PCCT APPARATUS, AND MATERIAL DECOMPOSITION METHODMay 2020December 2023Allow4330YesNo
16755334TRACKING CONTRAST ELEMENTS IN ULTRASOUND IMAGINGApril 2020November 2023Allow4620YesNo
16805442DETECTING FLUID FLOWS USING ULTRASOUND IMAGING SYSTEMSFebruary 2020October 2023Allow4350YesNo
16637284DEVICE, SYSTEM AND METHOD FOR DETERMINING A PHYSIOLOGICAL PARAMETER OF A SUBJECTFebruary 2020November 2024Allow5720NoYes
16741373SYSTEM AND METHODS FOR AUTOMATIC LESION CHARACTERIZATIONJanuary 2020October 2023Allow4531NoNo
16695974METHOD AND DEVICE FOR MEASURING A MEAN VALUE OF VISCO-ELASTICITY OF A REGION OF INTERESTNovember 2019October 2024Allow5950YesNo
16554138AUTOMATED OPTIC NERVE SHEATH DIAMETER MEASUREMENTAugust 2019August 2024Abandon6031NoNo
16487884REMOTELY CONTROLLED ULTRASONIC IMAGING SYSTEMAugust 2019May 2024Abandon5760YesNo
16462410SYNTHETIC MAGNETIC RESONANCE IMAGING AND MAGNETIC RESONANCE FINGERPRINTING WITH A CONTRAST AGENT, AND DETERMINATION OF A CONTRAST AGENT INJECTION PROTOCOLMay 2019January 2024Allow5650YesNo
16406630DYNAMIC 129Xe GAS EXCHANGE SPECTROSCOPYMay 2019November 2023Allow5431YesNo
16338884X-PLANE AND 3D IMAGING FOR ASYMMETRIC APERTURESApril 2019March 2024Allow5970YesNo
16373234ULTRASOUND DIAGNOSTIC APPARATUS AND ULTRASOUND SIGNAL PROCESSING METHODApril 2019December 2023Abandon5760YesNo
16366803Radiation Image Processing Apparatus and Radiation Image Processing MethodMarch 2019March 2025Abandon6060YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BEGEMAN, ANDREW W.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
99.9%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
2
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
100.0%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner BEGEMAN, ANDREW W - Prosecution Strategy Guide

Executive Summary

Examiner BEGEMAN, ANDREW W works in Art Unit 3798 and has examined 41 patent applications in our dataset. With an allowance rate of 53.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner BEGEMAN, ANDREW W's allowance rate of 53.7% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BEGEMAN, ANDREW W receive 3.10 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BEGEMAN, ANDREW W is 40 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +16.2% benefit to allowance rate for applications examined by BEGEMAN, ANDREW W. This interview benefit is in the 60% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.4% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 7.1% of cases where such amendments are filed. This entry rate is in the 3% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 45% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 44% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.